Clark & Elbing LLP

101 Federal Street Boston, MA 02110 Telephone 617-428-0200 Facsimile 617-428-7045 617-428-7046

Date: November 7, 2003

To: Examiner R. Zeman

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Facsimile No.: 703-746-3111

From: Susan M. Michaud

Reg. No. 42,885

Re: U.S. Serial No. 09/121,587

Attorney Docket No. 06132/033003

Pages: 6

6

From-CLARK & ELBING LLP

ATTORNEY DOCKET NO. 06132/033003

Certificate of Transmission by Facsimile: Date of Transmission: November 7, 2063

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Examiner listed below, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated above.

Susan M. Michaud

Signature of person transmitting facsimile

Printed name of person transmitting facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Thomas J. Chambers et al.

Art Unit:

1645

Serial No.:

09/121,587

Examiner:

R. Zeman

Filed:

July 23, 1998

Cust. No.:

21559

Title:

Chimeric Flavivirus Vaccines

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT AND REMARKS

Please amend the application as follows.

In the Claims:

Please cancel claims 11-13 and 17-29 as is indicated below.

1. (Previously Presented) A chimeric live, infectious, attenuated virus, comprising:

a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow fever virus prM-E protein is not expressed, and

integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that said prM-E protein of said second flavivirus is expressed, wherein the capsid protein of said chimeric virus is from yellow fever